Plinabulin, an inhibitor of tubulin polymerization, targets KRAS signaling through disruption of endosomal recycling by Cimino, Patrick J et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Plinabulin, an inhibitor of tubulin polymerization, targets KRAS signaling
through disruption of endosomal recycling
Cimino, Patrick J ; Huang, Lan ; Du, Lihua ; Wu, Yanping ; Bishop, Jamie ; Dalsing-Hernandez, Jessica
; Kotlarczyk, Kari ; Gonzales, Paul ; Carew, Jennifer ; Nawrocki, Steffan ; Jordan, Mary Ann ; Wilson,
Leslie ; Lloyd, G Kenneth ; Wirsching, Hans-Georg
Abstract: Constitutive activation of Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most
common oncogenic event in certain types of human cancer and is associated with poor patient survival.
Small molecule signaling inhibitors have improved the clinical outcomes of patients with various cancer
types but attempts to target KRAS have been unsuccessful. Plinabulin represents a novel class of agents
that inhibit tubulin polymerization with a favorable safety profile in clinical trials. In the present study,
the potency of plinabulin to inhibit tubulin polymerization and growth of KRAS-driven cancer cells was
characterized. efficacy of plinabulin was tested in two different mouse models; one being the RCAS/t-va
gene transfer system and the other being a xenograft model. cell culture tubulin polymerization assays
were used to complement the mouse models. There was improved survival in a KRAS-driven mouse
gene transfer glioma model, but lack of benefit in a similar model, without constitutively active KRAS,
which supports the notion of a KRAS-specific effect. This survival benefit was mediated, at least in
part, by the ability of plinabulin to inhibit tubulin polymerization and disrupt endosomal recycling. It
was proposed a mechanism of compromised endosomal recycling of displaced KRAS through targeting
microtubules that yields inhibition of protein kinase B, but not extracellular signal regulated kinase
(ERK) signaling, therefore lending rationale to combination treatments of tubulin- and ERK-targeting
agents in KRAS-driven cancer.
DOI: https://doi.org/10.3892/br.2019.1196
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-176137
Journal Article
Accepted Version
Originally published at:
Cimino, Patrick J; Huang, Lan; Du, Lihua; Wu, Yanping; Bishop, Jamie; Dalsing-Hernandez, Jessica;
Kotlarczyk, Kari; Gonzales, Paul; Carew, Jennifer; Nawrocki, Steffan; Jordan, Mary Ann; Wilson, Leslie;
Lloyd, G Kenneth; Wirsching, Hans-Georg (2019). Plinabulin, an inhibitor of tubulin polymerization,
targets KRAS signaling through disruption of endosomal recycling. Biomedical Reports, 10(4):218-224.
DOI: https://doi.org/10.3892/br.2019.1196
 1 
Title:  Plinabulin, an inhibitor of tubulin polymerization, targets KRAS  
signaling through disruption of endosomal recycling 
 
 
Authors: Patrick J. Cimino,1 Lan Huang,2 Lihua Du,2 Yanping Wu,2 Jamie Bishop,3  
Jessica Dalsing-Hernandez,4 Kari Kotlarczyk,4 Paul Gonzales,4 Jennifer S. 
Carew,5 Steffan T. Nawrocki,5 Mary Ann Jordan,3 Leslie Wilson,3 George 
K. Lloyd,2 Hans-Georg Wirsching,6 
 
  
Affiliations: 
1 Department of Pathology, University of Washington, Seattle, WA 
2 BeyondSpring Pharmaceuticals Inc., New York City, NY 
3 Biomolecular Science and Engring, University of California, Santa Barbara, CA 
4 Translational Drug Development Inc., Scottsdale, AZ 
5 Institute for Drug Development, University of Texas, San Antonio, TX ; Present 
Address: University of Arizona, Tucson, AZ. 
6 Department of Neurology, University Hospital Zurich, Zurich, CH. 
 
 
Corresponding Author:  
Hans-Georg Wirsching, MD 
Department of Neurology 
University Hospital Zurich 
Frauenklinikstr. 26 
CH-8091 Zurich 
Switzerland 
Phone: +41-44-255-5500 
Email: hans-georg.wirsching@usz.ch 
 
 
  
Running title: Tubulin inhibition targets KRAS signaling  
 
Keywords: Plinabulin; KRAS; Endosome; Tubulin; Cancer 
 
 
 
 
 
 2 
ABSTRACT 
Constitutive activation of KRAS is the most common oncogenic event in human cancers 
and is associated with poor patient survival. Small molecule signaling inhibitors have 
improved the clinical outcomes of patients with various cancer types, but attempts to 
target KRAS have been unsuccessful. Plinabulin represents a novel class of agents that 
inhibit tubulin polymerization with a favorable safety profile in clinical trials. Here, we 
characterize the potency of plinabulin to inhibit tubulin polymerization and growth of 
KRAS-driven cancer cells. In vivo efficacy of plinabulin was tested in two different 
mouse models; one being the RCAS/t-va gene transfer system and the other being a 
xenograft model. Cell culture including tubulin polymerization assays. In vitro cell culture 
tubulin polymerization assays were used to complement the mouse models. There was 
improved survival in a KRAS-driven mouse gene transfer glioma model, but lack of 
benefit in a similar model without constitutively active KRAS, supports the notion of a 
KRAS-specific effect. This survival benefit was mediated, at least in part, by the ability 
of plinabulin to inhibit tubulin polymerization and disrupt endosomal recycling. We 
propose a mechanism of compromised endosomal recycling of displaced KRAS through 
targeting microtubules that yields inhibition of Akt, but not ERK signaling, thus lending 
rationale to combination treatments of tubulin- and ERK-targeting agents in KRAS-
driven cancers.  
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INTRODUCTION 
Activating point mutations in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) are 
present in approximately 30% of human cancers, including the vast majority of 
pancreatic cancers and large fractions of lung, colon and breast cancers (1). Moreover, 
elevation of the activity of KRAS and other ras family members due to upstream 
signaling is very common throughout most types of cancer (2). KRAS is a small GTP-
ase that mediates survival, proliferation and cytoskeletal organization of cancer cells by 
transducing or enhancing down-stream signals of the MEK/extracellular signaling-
regulated kinase (ERK) and of the phosphoinositide 3-kinase (PI3K)/Akt signaling 
cascade (3). Presence of constitutively active KRAS is associated with chemotherapy 
resistance and poor patient outcome, but thus far attempts to directly target KRAS have 
failed (4). KRAS exerts its functions at the inner cellular membrane and requires 
continuous recycling of mislocalized protein through endosomes. The microtubule 
network is critically involved in this subcellular segregation and trafficking of endosomal 
recycling (5, 6). Drugs that target microtubules include taxanes and vinca alcaloids. 
These drugs are among the best studied, longest standing cancer drugs and act as 
microtubule stabilizers that slow or block mitosis at the metaphase–anaphase transition, 
eventually yielding apoptosis (7). Tissue penetration of taxanes and vinca alcaloids is 
however limited and the therapeutic index is low. 
 
Plinabulin (NPI-2358) is a synthetic analogue of halimide, an Aspergillus-derived natural 
product that targets the tubulin network through a mechanism that is distinct from that of 
taxanes and vinca alcaloids: instead of stabilization of polymerized microtubules, 
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plinabulin inhibits polymerization by interacting with the colchicine-binding domain of β-
tubulin (8, 9). Drugs that target the colchicine-binding domain were historically deemed 
too toxic to be effective anti-cancer agents, but novel compounds such as plinabulin are 
more specific and potent inhibitors of tubulin polymerization (7), and tissue penetration 
is more favorable compared to classic tubulin stabilizing drugs (10). Moreover, 
plinabulin showed a favorable safety profile and encouraging antitumor responses in 
two early phase clinical trials (10, 11). Based on these results, plinabulin is currently in 
phase III clinical development in combination with docetaxel, and in phase I/II in 
combination with nivolumab for advanced non-small cell lung cancer (NCT02504489, 
NCT02812667). Here we detail the inhibition of tubulin polymerization by plinabulin, 
report preclinical results of the efficacy of plinabulin in KRAS driven murine tumor 
models and outline effects of plinabulin on intracellular KRAS trafficking and down-
stream signaling. 
 
MATERIALS AND METHODS 
Compounds and Reagents  
Plinabulin was obtained from BeyondSpring Pharmaceuticals, Inc. (New York, NY), 
irinotecan was obtained from Teva Pharmaceuticals (Irvine, CA), docetaxel and 
paclitaxel were from Selleckchem (Houston, TX). For in vivo studies, all compounds 
were diluted in 5% dextrose for intraperitoneal (i. p.) or intravenous (i. v.) injection of 
indicated doses. For in vitro studies, all drugs were diluted in complete growth media 
with 1 % dimethyl-sulfoxide (DMSO). 
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Tubulin polymerization assays 
MTP preparations consisting of 70% tubulin and 30% microtubule-associated proteins 
(MAPs) were isolated from bovine brain, polymerized into microtubules and monitored 
by light scattering at 350 nm. Transmission electron microscopy was used to determine 
the mean length distribution of microtubules in the absence or presence of drug. Grids 
were viewed in a Jeol electron microscope-1200 EX11 at 2000X and 30,000X 
magnification.  The Zeiss MOPIII was used to determine microtubule length distributions 
and mean lengths for at least 100 microtubules per sample. 
 
Cell culture 
All cell lines were obtained from the American Type Culture Collection (ATCC, 
Manassas, VA). HCT-15, A549, and MDA-MB-231 cells were maintained in RPMI-1640 
medium (Lonza, Walkersville, MD). LoVo cells were maintained in F12-K medium 
(Corning/Cellgro, Manassas, VA). DF1 cells were maintained in Dulbecco’s Modified 
Eagle’s medium (DMEM). All cell culture media were supplemented with 10% fetal 
bovine serum (FBS; Seradigm, Radnor, PA) and housed in a 5% CO2 atmosphere at 
37°C, except DF1 cells were cultured at 39°C.  
 
Immunocytology 
A549 cells were seeded overnight on coverslips. Cells were fixed in 4% 
paraformaldehyde for 10 minutes, followed by permaeabilization utilizing 0.1% Triton in 
PBS for 5 minutes and blocking of unspecific binding with 5% donkey serum in PBS. 
These steps were done at room temperature, and washing with PBS was done between 
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any steps. Primary antibodies were rabbit anti-early endosomal antigen (EEA)1 (1:300, 
Thermo Scientific, Waltham, MA) and mouse anti-KRAS (1:100, Thermo Scientific), and 
were applied overnight at 4°C. After additional washing steps, cells were incubated with 
secondary donkey anti-rabbit-488 (1:200) and anti-mouse-Cy3 (1:200) antibodies in 
PBS with 5% donkey serum for 30 minutes at roomtemperature, followed by washing 
and addition of Hoechst 33342 Solution (1 μg/ml, Thermo Scientific) for 3 min, followed 
by washing, H2O for 3 min, 100% ethanol for 3 min and air-drying prior to embedding. 
Images were taken with a Zeiss LSM 780 NLO confocal microscope and quantification 
was done utilizing Image J (NIH, Bethesda, MD). 
 
In Vitro Cell Viability Assays 
Indicated cell lines were grown in standard serum-containing media. Cell viability was 
measured in triplicate utilizing the adenosine triphosphate (ATP)-based CellTiter-Glo® 
assay (Promega, Madison, WI). 
 
Murine xenograft models 
Animal studies were carried out in accordance with the Guide for the Care and Use of 
Laboratory Animals, as adopted by the U.S. National Institutes of Health. Animal 
research was prospectively approved by the Institutional Animal Care and Use 
Committee (Animal assurance institutional #A3226-01; Protocol #50842). Female 
athymic Foxn1nu mice between 4 to 6 weeks of age were obtained from Harlan 
(Madison, WI). For the HCT-15 and LoVo models, mice were anesthetized by isoflurane 
and inoculated with 0.1 ml of a 50% media / 50% matrigel mixture containing a 
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suspension of cultured tumor cells (1 x 107 cells/mouse for LoVo, 5 x 106 cells/mouse 
for HCT-15). As the tumors grew, the length (largest diameter) and width (smallest 
diameter) of tumors were measured using a digital caliper to determine the mean radius 
for tumor volume estimates assuming a spherical geometry and calculation per Vtumor= 
4/3 x π x r3. Automated calculation and documentation of tumor volume estimates was 
done using the animal study management software Study Director V.2.1.1 (Studylog 
Systems, San Francisco, CA). When tumor volume estimates exceeded a 
predetermined size 50-60 mm3, mice were randomized into control and treatment 
groups, being pair-matched by tumor size, and dosing was initiated (Day 1).  
 
RCAS/t-va glioma models 
N/t-va;Ink4a/Arf-/- mice expressing the avian t-va receptor under control of the nestin 
promoter were injected intracranially with DF-1 cells as hosts for the replicative avian 
retroviral gene transfer vector RCAS. Tumors were generated utilizing two RCAS 
vectors for the expression of platelet-derived growth factor B (PDGFB), and either 
KRAS encoding the activating mutation KRASG12A, or green fluorescent protein (GFP). 
DF-1 cells infected with these RCAS strains were injected into the brains of adult mice 
(aged 4 to 6 weeks) under the anesthetic isoflurane. One microliter of a 1:1 mixture for a 
total combined injection of 4 x 104 transfected DF-1 cell suspension was delivered using 
a 30-gauge needle attached to a Hamilton syringe. Coordinates were bregma 0 mm, 
lateral -0.5 mm (right of midline), and depth -1.5 mm from the dural surface. Mice were 
put on the study when they lost > 0.3 grams total over 2 consecutive days or displayed 
outward signs of a tumor. The mice were euthanized in a carbon dioxide chamber when 
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they lost more than 20% of their body weight, displayed a lack of mobility, inability to 
feed or weighed less than 14 grams for a male/ 12 grams for a female. Groups were 
treated with vehicle or plinabulin at 7.5 mg/kg twice per week for up to 10 weeks. 
 
RESULTS 
Plinabulin inhibits microtubule polymerization 
The overlapping binding sites of plinabulin and colchicine at the α/β-tubulin interface led 
us to first characterize and compare effects of both drugs on microtubule dynamics. In a 
cell-free MTP-containing model system, plinabulin inhibited microtubule formation more 
potently than colchicine, as measured by turbidity spectra (Figure 1A). The 
concentrations of plinabulin and colchicine at which polymerization was inhibited 50% 
(IC50) were 2.4 μM (standard deviation [SD] +/- 0.4, N=4 independent experiments) and 
7.6 μM (SD +/- 2.4, N=3), respectively. The tubulin polymerization profiles obtained in 
the presence of different concentrations of plinabulin or colchicine differed in two ways: 
First, the initial rate of increase in absorbance over time decreased with increasing drug 
concentrations of plinabulin, indicating that there is a lag period for microtubule 
formation. In contrast, the initial rate of polymerization is unchanged at all 
concentrations of colchicine. Second, microtubule formation in the presence of 
plinabulin does not reach steady state at high drug concentrations, as indicated by the 
absorbance values that increase linearly with time, whereas in the presence of high 
concentrations of colchicine steady state is readily reached. These data are suggestive 
of a reduction of the pool of soluble, assembly-competent tubulin in the presence of 
plinabulin. In contrast, colchicine binds nearly irreversibly and induces a rate-limiting 
 9 
conformational change in tubulin that, once incorporated into the lattice, inhibits further 
microtubule polymerization at substoichiometric concentrations (12). Transmission 
electron microscopy was performed to further validate these findings. No microtubule 
aggregates were identified in the presence of plinabulin 1.25 µM (Figure 1B) and 2.5 µM 
(data not shown). The mean microtubule length was however potently reduced to 34% 
of DMSO-treatment at 1.25 µM plinabulin, whereas colchicine 1.25 µM reduced the 
mean microtubule length to 63% (Figure 1C, Supplementary Figure 1). Next, we 
evaluated how these findings translated in a cellular system. The IC50 of plinabulin for 
inhibiting mitosis in MCF-7 breast cancer cells was 17 nM and mitosis was halted at the 
prometaphase (Supplementary Figure 2), suggesting that tubulin bound by plinabulin 
may not be assembly competent to be incorporated into microtubules.  
 
Plinabulin synergizes with chemotherapy in KRAS-driven xenograft cancer 
models 
In consideration of the limited activity of chemotherapy in various cancer types with 
constitutive KRAS activity, we sought to evaluate whether the distinct mechanism of 
action of plinabulin yielded anti-tumor activity in these cancers. In a panel of 8 human 
cell lines derived from pancreatic, colorectal and renal cancers, plinabulin inhibited 
growth in the nanomolar range in all cell lines, except for the pancreatic cancer cell line 
HPAC (Figure 2A). This led us to also explore putative anti-cancer effects of plinabulin 
in vivo in a panel of five KRAS mutated xenograft models. Contrasting in vitro results, 
plinabulin monotherapy failed to inhibit the growth of LoVo and HCT-15 colorectal 
cancer (Figure 2B, Supplementary Figure 3A) and exerted no more than a moderate 
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effect on the growth of MDA-MB-231 breast cancer alone (Figure 2C). The growth of the 
KRAS mutated DU-145 prostate cancer (Figure 2D) and A549 lung adenocarcinoma 
(Supplementary Figure 3B) models was neither affected by plinabulin monotreatment. 
However, in combination with standard chemotherapeutic agents administered in these 
cancers, we observed additive or synergistic effects of plinabulin on the inhibition of 
tumor growth, including combinations with the topoisomerase inhibitor irinotecan and 
with the tubulin targeting agents, paclitaxel and docetaxel (Figure 2, Supplementary 
Figure 3). These data point towards a modulation of anti-apoptotic signaling pathways 
rather than direct cytotoxic effects of plinabulin other than direct cytotoxicity and 
therefore led us to next evaluate down-stream KRAS signaling. 
 
Tubulin depolymerization yields displacement of KRAS to endosomes 
In non-small cell lung and other cancers, downstream effects of KRAS signaling include 
the activation of the MEK/ERK and PI3K/Akt pathways (3). Moreover, ERK is regulated 
by a variety of converging pathways that are activated under cellular stress including 
chemotherapy with tubulin-targeting agents, whereas the key activator of Akt is the 
KRAS target phosphoinositide 3-kinase (PI3K) (13). The proto-oncogene phosphatase 
and tensin homolog (PTEN) is in reverse the key inhibitor of PI3K, thus rendering intact 
PTEN a pre-requisite for KRAS-dependency of cancer cells (14). In PTEN proficient 
A549 lung cancer cells, disassembly of the microtubule network utilizing plinabulin 
concentrations in the range of its IC50 for in vitro tubulin depolymerization led to rapid 
accumulation of KRAS in early endosomes (mean endosomal EEA1-colocalized KRAS 
in DMSO vs Plinabulin = 2 vs 31 %, p<0.001, N=5, Figure 3A). Moreover, overall KRAS 
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levels were decreased upon plinabulin treatment, which may reflect lysosomal 
degradation. The two key down-stream effectors of KRAS signaling, ERK and Akt, were 
differently affected by plinabulin treatment and subsequent KRAS depletion: ERK 
phosphorylation was increased, but Ser473-phosphorylation of Akt was reduced (Figure 
3B). These findings indicate that displacement of KRAS and potentially other tubulin-
dependent kinases may yield decreased downstream PI3K signaling, while alternative 
signaling pathways act on the ERK signaling cascade. 
 
Plinabulin prolongs survival in a RAS-driven glioma model 
Next, we aimed to evaluate the specificity of plinabulin effects on KRAS driven cancers 
in a simplified model system that was not biased by co-mutations. For this purpose we 
employed two PTEN-proficient glioma gene transfer models that differed solely in the 
absence or presence of constitutively active KRAS. Gliomas were generated in the 
brains of Ink4a/Arf-deficient mice expressing the avian t-va receptor under control of the 
nestin promoter (N/t-va:Ink4a/Arf-/-) to allow gene transfer utilizing the avian retrovirus 
RCAS for overexpression of PDGFB and GFP or KRASG12A. Although activating KRAS 
mutations are rare in gliomas, hyperactivation of RAS signaling is a key component of 
gliomagenesis and histologically, these gliomas resemble the human disease (15). 
Moreover, given that brain metastases are an important cause of cancer-related death 
(16-18), we aimed to evaluate whether plinabulin was capable of penetrating the blood 
brain barrier to a relevant extent. Penetration of the blood-brain barrier by plinabulin is 
supported by the observation that in a Quantitative Hole Body Autoradioluminogrphy 
study, plinabulin rapidly entered into the brain parenchyma (Supplemental Figure 4). 
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Treatment with plinabulin prolonged survival in KRAS-expressing gliomas (Figure 3C), 
but not in tumors that were solely driven by PDGFB and Ink4a/Arf loss (Figure 3D), thus 
confirming penetration of the blood brain barrier to a relevant extent and supporting the 
notion of efficacy of plinabulin specifically in KRAS-mutated tumors.  
 
DISCUSSION 
KRAS-driven cancers pose a major therapeutic challenge. To date, precision medicine 
approaches have failed to directly target KRAS (4), and standard chemotherapy has 
only limited efficacy in KRAS-mutated cancers (19). KRAS exerts its oncogenic function 
primarily by activating the MEK/ERK and PI3K/Akt signaling cascades, but dual 
inhibition of both pathways is deemed too toxic to be clinically applicable. However, 
targeting microtubules has been suggested as a means to compromise endosomal 
recycling of KRAS (20) and combination of docetaxel with the MEK-inhibitor selumetinib 
dramatically improved the survival of patients with KRAS-driven non-small cell lung 
cancer compared to docetaxel alone in an exploratory, randomized phase II trial (21).  
 
Our preclinical study supports the concept of combining tubulin-targeting agents with 
inhibitors of the MEK/ERK signaling axis: upon plinabulin treatment, we observed rapid 
accumulation of KRAS in endosomal vesicles and a potent inhibitory effect on Akt 
phosphorylation, but a simultaneous increase in ERK activation that may compensate 
for Akt inhibition. The underlying mechanism of this ERK activation likely reflects a 
stress response through alternative kinases such as the stress-activated protein kinases 
(22). 
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Compensatory ERK activation may also explain the lack of growth inhibition of most 
xenograft models tested here by plinabulin monotherapy. Moreover, effective targeting 
of KRAS signaling through combined treatment with tubulin-targeting agents and 
MEK/ERK inhibitors may require intact PTEN, as disinhibition of PI3K signaling upon 
loss of PTEN activity renders Akt signaling independent of KRAS. 
 
Plinabulin may be well suited for such potentially toxic combination treatments, given its 
favorable safety profile and tolerability in clinical trials. Of note, tubulin polymerization 
assays reported here indicate that plinabulin exerts its effects by a mechanism that is 
distinct and potentially less toxic than that of colchicine and established anti-cancer 
tubulin-targeting drugs: plinabulin binds less avidly to tubulin and its binding may be 
more readily reversible. Moreover, activity in a mutant KRAS-driven brain tumor model 
underscores the favorable pharmacokinetics profile of plinabulin, including crossing of 
the blood brain barrier. 
 
In summary, our preclinical study supports the inclusion of tubulin-targeting agents in 
future developments of combination treatments against KRAS-driven cancers. 
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FIGURE LEGENDS 
Figure 1. Plinabulin inhibits tubulin polymerization. A, turbidity spectra of cell-free 
microtubule protein polymerization in the presence of dimethyl sulfoxide (DMSO) drug 
vehicle, or indicated concentrations of plinabulin (upper panel) or colchicine (lower 
panel). B, microtubules were allowed to polymerize in the presence of DMSO or 1.25 
µM plinabulin for 60 minutes prior to electron microscopy. C, frequency histograms of 
mean microtubule lengths at steady state in the presence of DMSO or plinabulin 2.5 
µM. 
 
 
Figure 2. Plinabulin inhibits tumor growth in KRAS mutated cancer models. A, in vitro 
growth inhibition of KRAS mutated cancer cell lines by plinabulin. 1.000 cells per well 
were seeded in 96-well plates in triplicate overnight and treated in serum-free medium 
with plinabulin at log2 increments of 1 nM-16.4 µM plinabulin in 0.2% DMSO or DMSO 
0.2% alone for 72 h prior to assessment of adenosine triphosphate content. C-D, human 
KRAS mutated LoVo colon cancer (B), MDA-MB-231 breast cancer (C) and DU-145 
prostate cancer (D) xenograft models were injected as indicated with 5% dextrose 
solution (vehicle) i.p. or i.v., plinabulin (plin) 7.5 mg/kg i.p. on 5 subsequent days, 
irinotecan 80 mg/kg i.p. once weekly for 3 weeks (B), paclitaxel 16 mg/kg i.p. on 5 
subsequent days (C), and docetaxel 12.5 mg/kg i.v. on days 1, 3 and 5 (D). Tumor 
volumes were measured twice weekly in N=10 mice per treatment group. Linear 
regression was performed to determine differences in tumor growth over time. n.s., not 
significant, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.  
 
Figure 3. Plinabulin yields endosomal accumulation of KRAS. A, A549 cells were 
treated with 0.2% DMSO (upper panel) or 1.25  µM plinabulin (lower panel) for 2 hours 
prior to immunofluorescence stainings of DNA utilizing 4,6-Diamidino-2-phenylindole 
(DAPI, blue), the early endosomal antigen EEA-1 (green) and KRAS (red). Scale bar, 
10 µm. B, immunoblot analysis of A549 cells serum-starved overnight and treated with 
1% DMSO or 1.25  µM plinabulin for 2 hours prior to treatment with 100 ng/ml epithelial 
growth factor (EGF) for indicated times. C, D, Mouse gliomas were generated in N/t-
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va;Ink4a/Arf-/- mice by transduction with RCAS-PDGF and RCAS-KRASG12A (C), or 
RCAS-GFP (D). Mice were treated with 5% dextrose solution i.p. (vehicle) or plinabulin 
7.5 mg/kg i.p. for 5 subsequent days. Weight loss was utilized as a surrogate for tumor 
formation to determine the timepoint of treatment initialization. Survival was defined as 
the time from treatment until sacrifice. The log rank test was applied to determine 
survival difference between groups. 
	
	
	
	


	
	
	
	
	
Supplementary	Figure	4	
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